The Outlook for JAK Inhibitors in Myelofibrosis
Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis.
Clinical Pearls
Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis.
- No JAK inhibitor can elicit PR or CR in myelofibrosis
- JAK inhibitors have good palliative value and are able to help a patient gain weight and shrink their spleen
- An oncologist wants to cure cancer or put it to sleep JAK inhibitors will never rise to that level
- There remains a need for pilot studies with innovative drugs that could potentially clear cancer
Recent Videos
Related Content
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
November 15th 2024Article
The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly diagnosed Ph-positive CP- and AP-CML, or for those resistant or intolerant to prior therapy, including imatinib.
Read More
